<DOC>
	<DOCNO>NCT01205581</DOCNO>
	<brief_summary>This open label-study Fluzone HD , high-dose form trivalent , inactivate influenza vaccine ( TIV ) , vs. Fluzone , standard-dose form TIV . Subjects cancer HIV vaccinate twice one two vaccine evaluate development immune response .</brief_summary>
	<brief_title>Immunogenicity Fluzone HD , A High Dose Influenza Vaccine , In Children With Cancer HIV</brief_title>
	<detailed_description>The primary objective study compare immune response Fluzone HD , high-dose , trivalent influenza vaccine ( TIV ) , Fluzone , standard-dose TIV , child cancer child HIV . The secondary objective study : - Describe safety reactogenicity high-dose standard-dose TIV . - Compare immunogenicity induce 1 dose , compare 2 dos , high-dose standard-dose TIV . - Describe relationship baseline lymphocyte numbers/function robustness/durability immune response .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Age 3 year ( past 3rd birthday ) 21 year age ( yet reach 22nd birthday ) time entry study . Written informed consent ( assent , applicable ) obtain . Participant diagnosis cancer HIV . If subject cancer , currently receive chemotherapy /or radiotherapy treatment cancer receive chemotherapy past 12 week Exclusion Criteria Severe hypersensitivity egg proteins component Fluzone , lifethreatening reaction previous administration influenza vaccine ; History GuillainBarreÂ´ syndrome subject subject 's family ( parent , sibling , half sibling , child ) ; Not willing agree acceptable birth control three month study immunization</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Fluzone</keyword>
	<keyword>Trivalent Influenza Vaccine</keyword>
</DOC>